{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106227","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.091633+00:00","generated_at":"2026-05-17T15:39:01.035582+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kymera Q2 net loss $76.6M; cash ~$1B; KT-621 Phase 1 data positive; Gilead CDK2 deal up to $750M","bullets":["Net loss widened to $76.6M in Q2 2025 ($42.1M Q2 2024); R&D spend rose to $78.4M from $59.2M.","Cash ~$1B as of July 31, 2025 (including $250M equity offering and Gilead upfront); runway into H2 2028.","KT-621 Phase 1 healthy volunteer: deep STAT6 degradation, safety undifferentiated from placebo; Phase 1b AD data expected 4Q25; Phase 2b AD/asthma start 4Q25/1Q26.","Gilead partnership for CDK2 molecular glue: up to $750M total payments including up to $85M upfront/option; Kymera leads research.","Sanofi to advance KT-485 (IRAK4) into Phase 1 in 2026; $20M preclinical milestone achieved."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106227","json":"https://secwatch.observer/filing/0000950170-25-106227.json","markdown":"https://secwatch.observer/filing/0000950170-25-106227.md","text":"https://secwatch.observer/filing/0000950170-25-106227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025106227/0000950170-25-106227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025106227/kymr-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:39:01.035582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}